193 related articles for article (PubMed ID: 25437128)
1. Pitfalls in dosing vancomycin.
Koppula S; Ruben S; Bangash F; Szerlip HM
Am J Med Sci; 2015 Feb; 349(2):137-9. PubMed ID: 25437128
[TBL] [Abstract][Full Text] [Related]
2. Achievement of Therapeutic Vancomycin Trough Serum Concentrations with Empiric Dosing in Neonatal Intensive Care Unit Patients.
Ringenberg T; Robinson C; Meyers R; Degnan L; Shah P; Siu A; Sturgill M
Pediatr Infect Dis J; 2015 Jul; 34(7):742-7. PubMed ID: 25629890
[TBL] [Abstract][Full Text] [Related]
3. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections.
Frymoyer A; Guglielmo BJ; Hersh AL
Pediatr Infect Dis J; 2013 Oct; 32(10):1077-9. PubMed ID: 23652479
[TBL] [Abstract][Full Text] [Related]
4. Innovative approaches to optimizing the delivery of vancomycin in individual patients.
Pai MP; Neely M; Rodvold KA; Lodise TP
Adv Drug Deliv Rev; 2014 Nov; 77():50-7. PubMed ID: 24910345
[TBL] [Abstract][Full Text] [Related]
5. Initial vancomycin dosing protocol to achieve therapeutic serum concentrations in patients undergoing hemodialysis.
Zelenitsky SA; Ariano RE; McCrae ML; Vercaigne LM
Clin Infect Dis; 2012 Aug; 55(4):527-33. PubMed ID: 22573855
[TBL] [Abstract][Full Text] [Related]
6. Vancomycin dosing in critically ill trauma patients: The VANCTIC Study.
Villanueva RD; Talledo O; Neely S; White B; Celii A; Cross A; Kennedy R
J Trauma Acute Care Surg; 2019 Nov; 87(5):1164-1171. PubMed ID: 31464871
[TBL] [Abstract][Full Text] [Related]
7. Acute Kidney Injury Associated With Vancomycin When Laxity Leads to Injury and Findings on Kidney Biopsy.
Katikaneni M; Lwin L; Villanueva H; Yoo J
Am J Ther; 2016; 23(4):e1064-7. PubMed ID: 26035034
[TBL] [Abstract][Full Text] [Related]
8. Individualized vancomycin dosing in obese patients: a two-sample measurement approach improves target attainment.
Hong J; Krop LC; Johns T; Pai MP
Pharmacotherapy; 2015 May; 35(5):455-63. PubMed ID: 26011138
[TBL] [Abstract][Full Text] [Related]
9. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.
Hidayat LK; Hsu DI; Quist R; Shriner KA; Wong-Beringer A
Arch Intern Med; 2006 Oct; 166(19):2138-44. PubMed ID: 17060545
[TBL] [Abstract][Full Text] [Related]
10. Exploration of optimal dosing regimens of vancomycin in patients infected with methicillin-resistant Staphylococcus aureus by modeling and simulation.
Lim HS; Chong YP; Noh YH; Jung JA; Kim YS
J Clin Pharm Ther; 2014 Apr; 39(2):196-203. PubMed ID: 24428720
[TBL] [Abstract][Full Text] [Related]
11. Impact of a hospitalwide increase in empiric pediatric vancomycin dosing on initial trough concentrations.
Frymoyer A; Guglielmo BJ; Wilson SD; Scarpace SB; Benet LZ; Hersh AL
Pharmacotherapy; 2011 Sep; 31(9):871-6. PubMed ID: 21923588
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis.
Stockmann C; Sherwin CM; Zobell JT; Lubsch L; Young DC; Olson J; Noyes BE; Ampofo K; Spigarelli MG
Pharmacotherapy; 2013 Dec; 33(12):1288-96. PubMed ID: 23824677
[TBL] [Abstract][Full Text] [Related]
13. Continuous infusion vancomycin for treatment of methicillin-resistant Staphylococcus aureus in cystic fibrosis patients.
Fung L
Ann Pharmacother; 2012 Oct; 46(10):e26. PubMed ID: 23032658
[TBL] [Abstract][Full Text] [Related]
14. Vancomycin Dosing Considerations in a Real-World Cohort of Obese and Extremely Obese Patients.
Morrill HJ; Caffrey AR; Noh E; LaPlante KL
Pharmacotherapy; 2015 Sep; 35(9):869-75. PubMed ID: 26343549
[TBL] [Abstract][Full Text] [Related]
15. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of vancomycin serum trough concentrations and outcomes in meticillin-resistant Staphylococcus aureus bacteraemia.
Arshad S; Shoyinka A; Chen A; Jacobsen G; Zervos M
Int J Antimicrob Agents; 2012 Nov; 40(5):474-5. PubMed ID: 22883416
[No Abstract] [Full Text] [Related]
17. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia.
Jeffres MN; Isakow W; Doherty JA; Micek ST; Kollef MH
Clin Ther; 2007 Jun; 29(6):1107-15. PubMed ID: 17692725
[TBL] [Abstract][Full Text] [Related]
18. Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort.
Kullar R; Davis SL; Taylor TN; Kaye KS; Rybak MJ
Pharmacotherapy; 2012 Mar; 32(3):195-201. PubMed ID: 22392452
[TBL] [Abstract][Full Text] [Related]
19. Dosing vancomycin in the super obese: less is more.
Crass RL; Dunn R; Hong J; Krop LC; Pai MP
J Antimicrob Chemother; 2018 Nov; 73(11):3081-3086. PubMed ID: 30203073
[TBL] [Abstract][Full Text] [Related]
20. In vivo antibacterial activity and pharmacological properties of the membrane-active glycopeptide antibiotic YV11455.
Yarlagadda V; Konai MM; Manjunath GB; Prakash RG; Mani B; Paramanandham K; Ranjan SB; Ravikumar R; Chakraborty SP; Roy S; Haldar J
Int J Antimicrob Agents; 2015 Jun; 45(6):627-34. PubMed ID: 25900818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
